CanSino (Convidecia) for COVID-19: living meta-analysis of clinical studies

Study explorer (study characteristics and results) method abbreviations pdf xlsx

display ongoing studies
Study	Ref.	Design	studied treatment	control treatment	patients	study risk of bias	sample sizes	Results
COVID-19 prophylaxis (excluding children) meta-analysis
Li J NCT04892459		RCT	CanSino (Convidecia)	CoronaVac (SinoVac)	COVID-19 prophylaxis (excluding children)	NA	147/152	inconclusive	No thromboses, vaccine-related anaphylaxis or other serious adverse events were observed in any of the groups by day 28 after the booster

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).

Study explorer (study characteristics and results) method abbreviations pdf xlsx

COVID-19 prophylaxis (excluding children) meta-analysis